Research programme: proteases - Bayer Schering Pharma/Pfizer

Drug Profile

Research programme: proteases - Bayer Schering Pharma/Pfizer

Latest Information Update: 23 Mar 2010

Price : $50

At a glance

  • Originator Direvo Biotech
  • Developer Bayer Schering Pharma; Pfizer
  • Class Peptide hydrolases
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 30 Sep 2008 DIREVO Biotech has been acquired and merged into Bayer Schering Pharma
  • 12 Nov 2007 Early research in Undefined indication in Germany (unspecified route)
  • 12 Nov 2007 Early research in Undefined indication in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top